Clinical Research Studies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Advanced Malignant Tumors
• Age: Between 18 years - 90 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1. Patients must have histologic or cytological confirmation of a malignancy that is advanced with measurable disease. Tumor histologies include skin cancers, lung cancer, head and neck cancer, bladder cancers, pancreatic cancer, cervical, breast, and ovarian cancers, sarcomas, Hodgkin lymphoma, and Diffuse large B-Cell lymphoma. 2. Patients with prior exposure to therapy with any agent specifically targeting checkpoint pathway inhibition (such as anti-PD-(L)1, anti-PDL-2, anti-LAG-3, and anti-CTLA-4 antibody) are permitted after a washout period of any time greater than 4 weeks from the last treatment. 3. Patients must be able to swallow pills or capsules.
  

You may not be eligible for this study if the following are true:

• 1. Patients with CNS metastases, untreated CNS metastases, or with the CNS as the only site of disease are excluded 2. Patients with a history or presence of G6PD deficiency, cytochrome b5 reductase deficiency. 3. History of congenital or autoimmune hemolytic disorders.